ArticleKorean journal of radiology2025
Prognostic Implication of Right Ventricular Hypertrophy in Patients With Hypertrophic Cardiomyopathy.
Article in Korean journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the prognostic significance of right ventricular hypertrophy (RVH) in patients with hypertrophic cardiomyopathy (HCM) using cardiac magnetic resonance imaging (CMR) and to assess its incremental value when incorporated into the established 5-year sudden cardiac death (SCD) risk prediction model. MATERIALS AND
methodsThis retrospective study included 320 patients with HCM who underwent CMR and echocardiography between 2007 and 2019. RVH was defined as a right ventricular wall thickness of ≥5 mm. The primary event was heart failure (HF) hospitalization. The secondary events were a composite of HF hospitalization, cardiovascular death, and heart transplantation. The prognostic role of RVH was assessed using Kaplan-Meier survival analysis, Cox proportional hazards regression, and model performance metrics, including time-dependent receiver operating characteristic curve analysis for a 5-year follow-up and Harrell's C-index.
resultsAmong 320 patients (mean age 57.5 ± 12.8 years; 66.3% men), 65 (20.1%) had RVH. Over a median follow-up of 7.7 years, 28 (8.8%) patients experienced HF hospitalization, and 34 (10.6%) experienced composite adverse events. In multivariable Cox models, RVH was an independent predictor of both events: HF hospitalization (hazard ratio [HR] = 3.19, 95% confidence interval [CI] = 1.23-8.28,
conclusionCMR-detected RVH independently predicts adverse events in patients with HCM. Incorporating RVH into a conventional risk model may enhance its predictive performance, supporting the importance of routine biventricular assessments in HCM evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.